Abstract
The 16p11.2 deletion impacts in a quantitative and independent manner FSIQ, behaviour and body mass index, possibly through direct influences on neural circuitry. Although non-specific, these features are clinically significant and reproducible. Lastly, this study demonstrates the necessity of studying large patient cohorts ascertained through multiple methods to characterise the clinical consequences of rare variants involved in common diseases.
Introduction
This landmark study characterizes the 16p11.2 deletion—a 600 kb genomic loss—as a major driver of both neurodevelopmental disorders and metabolic dysfunction. Identifying a "risk gene" is only the first step; the real challenge lies in deep phenotyping to understand the full range of physical and mental effects. While the 16p11.2 deletion was previously associated with Autism Spectrum Disorder (ASD) and obesity, earlier studies often suffered from ascertainment bias. This research defines the "natural history" of the deletion by examining a massive, diverse cohort of 285 carriers, including relatives who carry the deletion but were never formally diagnosed.
Genomic Context and Methods
The study pooled data from the 16p11.2 European Consortium and the Simons Variation in Individuals Project (Simons VIP). Deletions were confirmed using high-density chromosomal microarrays (aCGH).
Clinical evaluations included standardized IQ tests (WISC/WAIS), psychiatric interviews (ADI-R/ADOS), and longitudinal growth measurements. The team used Z-scores to normalize body mass index (BMI) and head circumference (HC) across different ages and genders, allowing them to track growth trajectories over time.
Key Insights
- The "30-Point Drop": The deletion acts as a quantitative "tax" on intelligence. On average, carriers have a Full Scale IQ (FSIQ) about 32 points (2 standard deviations) lower than their non-carrier relatives.
- Independence of Traits: Crucially, the drop in IQ and the increase in BMI are independent effects of the deletion on different neural circuits (cognitive vs. metabolic).
- Neurodevelopmental Instability: While only 15% met full ASD criteria, over 80% had some psychiatric or language disorder, suggesting a broad neurodevelopmental impact rather than a single specific disease.
- Early Brain Overgrowth: Carriers show rapid head circumference increase in infancy (+1.74 Z-score), mirroring growth patterns seen in idiopathic autism.
Clinical Results
- Cognition: Mean FSIQ for carriers was 74, compared to ~108 in non-carrier relatives. Verbal IQ was typically lower than non-verbal IQ.
- Metabolism: Obesity is highly penetrant, with a 43-fold increased risk for morbid obesity. By age 7, 50% of carriers are obese, rising to 75% in adulthood.
- Neurology & Speech: Seizures were present in 24% of carriers. A staggering 83% required speech therapy during childhood, and gross motor delays were common.
Limitations and Future Directions
The 600 kb region contains 29 genes. While the study identifies the region as the culprit, pinpointing specific genes for specific symptoms remains a challenge.
Candidate genes include KCTD13 for head size and PRRT2 for seizures. Furthermore, the lack of durable weight loss in this population highlights an urgent need for pharmacological interventions targeting the specific metabolic pathways disrupted by the 16p11.2 deletion.
Summary updated